1
Masakuni Okuhara, Hirokazu Tanaka, Toshio Goto, Tohru Kino, Hiroshi Hatanaka: Method for immunosuppression. Fujisawa Pharmaceutical Company, Oblon Spivak McClelland Maier & Neustadt, May 29, 1990: US04929611 (58 worldwide citation)

This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: ##STR1## to a pr ...


2
Watanabe Tomoko: Methods of inducing differentiation of regulatory t-cells and proliferating the same with gpi anchor protein agonist and medicinal composition therefor. Kirin Brewery, February 7, 2007: EP1749538-A1 (8 worldwide citation)

An object of the present invention is to provide a method for inducing the differentiation of and/or promoting the proliferation of regulatory T cells, an immunosuppressive method using these methods, and pharmaceutical compositions for use in these methods. Furthermore, a method for inducing the di ...


3
Takayuki Yamazaki, Fumio Sugawara, Keisuke Ohta, Kazuyoshi Masaki, Kotaro Nakayama, Kengo Sakaguchi, Noriyuki Sato, Hiroeki Sahara, Tatsuya Fujita: Sulfoquinovosylacylglycerol derivative, and use thereof as medicaments. Toyo Suisan Kaisha, Frishauf Holtz Goodman & Chick P C, February 11, 2003: US06518410 (4 worldwide citation)

A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1):


4
Jonathan L Kiel: Method for immunosuppression. The United States of America represented by the Secretary of the Air Force, Stanton E Collier, Donald J Singer, August 23, 1988: US04766150 (3 worldwide citation)

A composition and process for suppressing the immune system of animals in which an effective amount of 3-aminotyrosine is administered which suppresses the endogenous immune system of animals.


5
Mark S Pasternack, Herman S Eisen: Cytotoxic T lymphocte serine esterase and method for stimulation and inhibition. Massachusetts Institute of Technology, Kilpatrick & Cody, May 21, 1991: US05017489 (2 worldwide citation)

Antibodies, nucleic acid sequences, and methods for inhibition of lysis for a novel serine esterase produced by both murine and human cytotoxic T lymphocytes. The serine esterase has an apparent molecular weight of approximately 28,000-31,000, as determined by SDS gel electrophoresis under reducing ...


6
Kimishige Ishizaka: Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor. La Jolla Institute for Allergy and Immunology, Fish & Richardson P C, October 15, 1996: US05565338 (2 worldwide citation)

The present invention provides antigen-specific human glycosylation inhibiting factor (GIF) and a method for immunosuppression of a specific immune response. Preferably, the antigen-specific GIF is directed toward an allergen. Hybridoma cell lines, ATCC HB 10472 and 10473, are provided as exemplary ...


7
Blasczyk Rainer, Ferreira de, Figueiredo Constanca Sofia, Seltsam Axel: (De) Verbindungen und verfahren zur immunsuppression, (En) Compounds and method for immunosuppression. Medizinische Hochschule Hannover, Blasczyk Rainer, Ferreira de, Figueiredo Constanca Sofia, Seltsam Axel, TARUTTIS Stefan, November 17, 2005: WO/2005/108572 (1 worldwide citation)

(EN) The invention relates to the influence exerted on the immune system or on the rejection reaction mediated by the immune system, between a transplant and a transplant patient, and autoimmune diseases. The aim of the invention is to reduce the expression of HLA I and/or HLA II, preferably until t ...


8
Christian Werner Gruber, Carsten Gruendemann: Cyclotides as immunosuppressive agents. Universitatsklinikum Freiburg, Medizinische Universitat Wien, Mueting Raasch & Gebhardt P A, December 25, 2018: US10159710

The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need t ...


9
Tomoyuki Odani, Hideaki Tada, Kimiho Yamada: Use of immunesuppressant receptor. ONO PHARMACEUTICAL, Sughrue Mion PLLC, January 2, 2018: US09856299

The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions ...


10
Tomoko Watanabe: Method for inducing differentiation of regulatory t cells usinggip-anchored protein agonist and pharmaceutical composition therefor ( as amended. Kirin Beer Kabushiki Kaisha, Foley And Lardner, August 2, 2007: US20070178072-A1

An object of the present invention is to provide a method for inducing the differentiation of and/or promoting the proliferation of regulatory T cells, an immunosuppressive method using these methods, and pharmaceutical compositions for use in these methods. Furthermore, a method for inducing the di ...